It has been designed to overcome adoption barriers that currently limit the use of predictive liver models within drug discovery workflows. This is so they can be used in earlier stages where larger scale comparative studies investigate the efficacy, disposition or safety of lead candidate drugs are required. The company says the system provides users with ‘a scalable solution, combining a significantly reduced cost-per-chip with increased run capacity’.
A multi-chip consumable plate containing 48 liver chips was also launched and this, the Liver-48 plate, miniaturizes the company’s human liver model for applications that include predicting drug-induced liver injury or determining drug metabolism/hepatic clearance, and the modelling of various prevalent liver diseases such as non-alcoholic steatohepatitis (NASH).
CN Bio says allowing 48 liver chip assays within one laboratory-standard Society for Biomolecular Screening (SBS) footprint, the plate supports the incorporation of replicates, controls and seven-point dose-response curves to improve data robustness and reproducibility. Multiple liver-48 plates can be run simultaneously to provide a total capacity of 144 chips per HT System, with potential to expand this further in response to consumer demand.
Together, the company says, the new technology enables the benefits of human relevant organ on chip (OOC) insights to be realized earlier in drug discovery, facilitating more confident decision making and the potential recovery of overlooked therapeutic candidates.
In support of new approach methodologies (NAMs) such as mucopolysaccharidoses (MPS), the US Food and Drug Administration (FDA) Modernization Act 2.0 has recently passed to remove the mandatory requirement for animal testing of developmental drugs for toxicity where enhanced performance is proven using in vitro alternatives.
The potential of MPS technology is further reinforced by the FDA’s decision to expand its collaborative research following several successful projects with CN Bio, most recently to investigate the company’s gut/liver model for human drug bioavailability studies.
Dr Paul Brooks, CEO at CN Bio, said: “The timing of this launch is particularly pertinent following significant US legislative changes, which should alleviate another barrier to more widespread OOC adoption and emphasises the potential of MPS to revolutionise drug discovery processes.
“Representing the next generation of OOC technology, the PhysioMimix Single-organ HT System extends and complements our existing portfolio, enabling scientists to pick the solution, or solutions, that best meet their research needs and phase of drug discovery, to bring more confident decision making to the process and the potential recovery of flawed drugs.”
CN Bio’s PhysioMimix OOC range of MPS is designed to reliably bridge the gap between existing preclinical methods and human studies. Complementing the simplicity of traditional in vitro cell culture and the complexity of in vivo animal models, the company's suite of hardware, consumables, and assay protocols, delivers accurate predictions where traditional approaches fall short. The company says the MPS enables users to culture primary human cells as 3D microtissues in a fully perfused microenvironment that incorporates key elements of the human immune system. Faithfully recreating the physiology and function of human tissues and organs in an in vitro environment, they offer a path forward for the testing of new human-specific therapeutic modalities and the insights from MPS to be realized earlier and at more stages of drug discovery than achieved to-date.
